Analysts' Views: Adamis Pharmaceuticl (ADMP)

Adamis Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Monday, June 12 with "Buy" rating. Finally, Raymond James Financial initiated coverage on shares of Adamis Pharmaceuticals in a report on Tuesday, September 12th. The company has market cap of $137.75 million. They set an outperform rating and a $7.00 price target for the company.

Taking a broader look at the analyst consensus, according to 3 analysts Adamis Pharmaceuticl (NASDAQ:ADMP)'s price will reach at $9.83 during 52 weeks.

Adamis Pharmaceuticl (NASDAQ:ADMP)'s revenue estimates for the current quarter are $4.05 Million according to 2 number of analysts, for the current quarter the company has high revenue estimates of $4.5 Million in contradiction of low revenue estimates of $3.6 Million. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock.

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. The company presently has a consensus rating of "Hold" and a consensus target price of $10.33. 2,327,305 shares of the company's stock traded hands, compared to its average volume of 736,994. Adamis Pharmaceuticals has a one year low of $2.55 and a one year high of $6.45.

The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 3.03%, and has a solid year to date (YTD) performance of 50.79% which means that the stock is constantly adding to its value from the previous fiscal year end price. Northern Trust Corp grew its stake in shares of Adamis Pharmaceuticals by 5.5% in the 2nd quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company's stock worth $200,000 after purchasing an additional 19,538 shares during the last quarter. Stonebridge Capital Advisors LLC grew its stake in shares of Adamis Pharmaceuticals by 22.2% in the 2nd quarter. Sterling Global Strategies LLC now owns 70,934 shares of the specialty pharmaceutical company's stock worth $369,000 after purchasing an additional 28,334 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Adamis Pharmaceuticals by 131.0% in the 3rd quarter. Leisure Capital Management now owns 145,909 shares of the specialty pharmaceutical company's stock worth $759,000 after purchasing an additional 9,832 shares during the last quarter. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.0935641849089 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. If you are viewing this report on another publication, it was stolen and republished in violation of US and global trademark & copyright laws. The short interest to Adamis Pharmaceuticals Corporation's float is 13.01%. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.